Tag Archives: Novartis
Why Novartis case will help innovation
The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board’s decision to deny patent protection to Novartis’s application
India’s patent case victory rattles Big Pharma
Will India, the world’s biggest provider of low-cost generic medicines, be the pariah or the pioneer of the pharmaceutical world? There is renewed focus on this thorny question in the wake of India’s Supreme Court’s dismissal of Swiss pharma giant
Novartis Ruling Reverberates Past India’s Borders
India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth
Attack on affordable medicines continues in EU-India trade negotiations
Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world 10 April, 2013, New Delhi- Thousands of people living with HIV, cancer patient groups & public health activists rallied
Apex court right to reject Novartis’s attempt
Novartis threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent
NDTV programme: Mr. Anand Grover speaking on the Novartis judgment
Mr. Anand Grover speaking on the Novartis judgment View the video
South Korean civil society groups welcome the ruling of the Supreme Court of India
[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and
Novartis denied cancer drug patent in landmark Indian case
Supreme court ruling paves way for generic companies to make cheap copies of Glivec in the developing world. The Indian supreme court has refused to allow one of the world’s leading pharmaceutical companies to patent a new version of a
